Patents by Inventor Peter William Stratford
Peter William Stratford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180133236Abstract: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: ApplicationFiled: January 12, 2018Publication date: May 17, 2018Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Simon LEPPARD, Pedro GARCIA, Brenda HALL, Maria Victoria Fajardo GONZALEZ
-
Patent number: 9901590Abstract: A composition for chemoembolotherapy of solid tumors comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: GrantFiled: December 8, 2015Date of Patent: February 27, 2018Assignee: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
-
Publication number: 20160106673Abstract: The present invention provides a composition comprising vesicles and encapsulated within the vesicles, nucleic acid comprising less than 1000 nucleotides, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. Methods of forming vesicles and methods of delivering nucleic acid, in particular, iRNA into cells, are also provided.Type: ApplicationFiled: December 28, 2015Publication date: April 21, 2016Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Giuseppe BATTAGLIA, Irene CANTON, Peter William STRATFORD
-
Publication number: 20160089389Abstract: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: ApplicationFiled: December 8, 2015Publication date: March 31, 2016Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Simon LEPPARD, Pedro GARCIA, Brenda HALL, Maria Victoria Fajardo GONZALEZ
-
Patent number: 9254258Abstract: The present invention provides a composition comprising vesicles and encapsulated within the vesicles, nucleic acid comprising less than 1000 nucleotides, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. Methods of forming vesicles and methods of delivering nucleic acid, in particular, iRNA into cells, are also provided.Type: GrantFiled: May 14, 2009Date of Patent: February 9, 2016Assignee: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard Lewis, Giuseppe Battaglia, Irene Canton, Peter William Stratford
-
Patent number: 9241895Abstract: A composition for chemoembolotherapy of solid tumors comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: GrantFiled: April 30, 2013Date of Patent: January 26, 2016Assignee: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
-
Publication number: 20140162969Abstract: There is provided a new use of microspheres comprising a water-insoluble, water-swellable polymer which is anionically charged at pH7, and electrostatically associated with the polymer, in releasable form, a cationically charged chemotherapeutic agent, in the manufacture of a composition for use in the treatment of a brain tumour, wherein in the treatment the composition is introduced into the brain and the chemotherapeutic agent is released from the microspheres, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water. Compositions comprising the microspheres and methods for the treatment of brain tumours are also provided.Type: ApplicationFiled: February 14, 2014Publication date: June 12, 2014Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Yiqing TANG, Peter William STRATFORD
-
Patent number: 8691791Abstract: There is provided a new use of microspheres comprising a water-insoluble, water-swellable polymer which is anionically charged at pH7, and electrostatically associated with the polymer, in releasable form, a cationically charged chemotherapeutic agent, in the manufacture of a composition for use in the treatment of a brain tumor, wherein in the treatment the composition is introduced into the brain and the chemotherapeutic agent is released from the microspheres, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water. Compositions comprising the microspheres and methods for the treatment of brain tumors are also provided.Type: GrantFiled: October 10, 2007Date of Patent: April 8, 2014Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Yiqing Tang, Peter William Stratford
-
Publication number: 20130243695Abstract: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: ApplicationFiled: April 30, 2013Publication date: September 19, 2013Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Simon LEPPARD, Pedro GARCIA, Brenda HALL, Maria Victoria Fajardo GONZALEZ
-
Patent number: 8455003Abstract: A composition for chemoembolotherapy of solid tumors comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: GrantFiled: April 20, 2012Date of Patent: June 4, 2013Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
-
Publication number: 20120276151Abstract: An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 ?m and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used to treat hypervascular tumours for instance colorectal metastases of the liver.Type: ApplicationFiled: October 27, 2011Publication date: November 1, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard Lewis, Peter William Stratford, Maria Victoria Gonzalez. Fajardo, Yiqing Tang
-
Publication number: 20120269722Abstract: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: ApplicationFiled: April 20, 2012Publication date: October 25, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Simon LEPPARD, Pedro GARCIA, Brenda HALL, Maria Victoria Fajardo GONZALEZ
-
Publication number: 20120201867Abstract: An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 ?m, and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used to treat hypervascular tumours for instance colorectal metastases of the liver.Type: ApplicationFiled: April 20, 2012Publication date: August 9, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Maria Victoria GONZALEZ.FAJARDO, Yiqing TANG
-
Patent number: 8221793Abstract: A composition for chemoembolotherapy of solid tumors comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: GrantFiled: September 15, 2008Date of Patent: July 17, 2012Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
-
Publication number: 20110293672Abstract: There is provided a composition comprising microspheres which comprise a water-insoluble, water-swellable polymer and associated with the polymer, in releasable form, a chemotherapeutic agent, for use in the treatment of a pancreatic tumour or cyst, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water, wherein the polymer is anionically charged at pH7 and the chemotherapeutic agent is cationically charged and electrostatically associated with the polymer. Also provided are methods of treating pancreatic tumours or cysts using this composition.Type: ApplicationFiled: November 25, 2009Publication date: December 1, 2011Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard Lewis, Peter William Stratford, Richard Edward John Forster
-
Patent number: 8052746Abstract: The present invention relates to a balloon expandable stent mounted on a balloon catheter, the entire assembly being overcoated with a coherent polymer coating, which is preferably substantially continuous over the circumference and, more preferably, axial length of the stem on the balloon. The polymer coating improves retention of the stent on the balloon during delivery and does not adversely effect the deployment characteristics, nor the balloon failure characteristics. The product is made by mounting the stent on the balloon and coating the assembly with a liquid coating composition containing a suitable polymer followed by curing of the coating. The polymer is biocompatible and preferably crosslinkable in the coating composition, and crosslinked in the final product. A suitable polymer is formed from monomers including a zwitterionic, preferably a phosphoryl choline, group, and monomers including a trialkoxysilyl group.Type: GrantFiled: July 23, 2007Date of Patent: November 8, 2011Assignee: Biocompatibles LimitedInventors: Peter William Stratford, Alistair Stewart Taylor, Vincent James O'Byrne, John Tom Clarke, Denis Dominic Healy
-
Publication number: 20110236431Abstract: The present application refers to the use of cells, e.g. mesenchymal stem cells or mesenchymal stromal cells, or any further suitable cell, encoding and secreting GLP-1, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof, for the treatment of acute myocardial infarction (AMI or Ml), wherein the cells, encoding and secreting GLP-1, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof, are encapsulated in a (spherical) microcapsule to prevent a response of the immune system of the patient to be treated. The present application also refers to the use of these (spherical) microcapsule(s) or of a pharmaceutical composition containing these cells or (spherical) microcapsule(s) for the treatment of acute myocardial infarction (AMI or Ml).Type: ApplicationFiled: September 11, 2009Publication date: September 29, 2011Applicant: BIOCOMPATIBLES UK LTD.Inventors: Christine Wallrapp, Andrew Lennard Lewis, Peter William Stratford, Eric Thoenes
-
Publication number: 20110151013Abstract: The present invention provides a composition comprising vesicles and encapsulated within the vesicles, nucleic acid comprising less than 1000 nucleotides, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. Methods of forming vesicles and methods of delivering nucleic acid, in particular, iRNA into cells, are also provided.Type: ApplicationFiled: May 14, 2009Publication date: June 23, 2011Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard Lewis, Giuseppe Battaglia, Irene Canton, Peter William Stratford
-
Patent number: 7794775Abstract: The present invention relate to a balloon expandable stent mounted on a balloon catheter, the entire assembly being overcoated with a coherent polymer coating, which is preferably substantially continuous over the circumference and, more preferably, axial length of the stent on the balloon. The polymer coating improves retention of the stent on the balloon during delivery and does not adversely effect the deployment characteristics, nor the balloon failure characteristics. The product is made by mounting the stent on the balloon and coating the assembly with a liquid coating composition containing a suitable polymer followed by curing of the coating. The polymer is biocompatible and preferably crosslinkable in the coating composition, and crosslinked in the final product. A suitable polymer is formed from monomers including a zwitterionic, preferably a phosphoryl choline, group, and monomers including a trialkoxysilyl group.Type: GrantFiled: November 16, 2005Date of Patent: September 14, 2010Assignee: Biocompatibles LimitedInventors: Peter William Stratford, Alistair Stewart Taylor, Vincent James O'Byrne, John Tom Clarke, Denis Dominic Healy
-
Patent number: 7754272Abstract: An implant having a coating comprising a polymer matrix is swollen in a pharmaceutical solution whereby pharmaceutically active compound is imbibed into the polymer matrix. When the product is implanted, release of the pharmaceutically active compound from the coating takes place. The polymer is preferably formed from ethylenically unsaturated monomers including a zwitterionic monomer, most preferably 2-methacryloyloxyethyl-2?-trimethylammoniumethyl-phosphate inner salt. The monomers from which the polymer is formed may further include surface binding monomers, such as hydrophobic group containing monomers, and crosslinkable monomers, the content of which may be used to control the swellability. Preferably the implant is a stent and the coating of polymer on the exterior wall surface is thicker than the coating of polymer on the interior surface. Release of the drug may be controlled by selection of comonomers. The implant is suitably a stent for use in the cardiovascular system.Type: GrantFiled: May 11, 2004Date of Patent: July 13, 2010Assignee: Biocompatibles IK LimitedInventors: Lee Rowan, Peter William Stratford, Alistair Stewart Taylor, Terrence Albert Vick